Amarin closed at $11.67 on Nov 12, down 0.34%, 31.3% below its 52-week closing high. Volume of 60.2K shares was 0.74× its 20-day average (below normal).
Split-adjusted performance: +0.5% over one month, -21.0% over six months, -27.5% over one year.
In the quarter ended Sep 30, 2026, revenue was $39.55M, down 20.4% from a year earlier, with a net margin of 0.6%.
Short interest was 537.9K shares at the Oct 30 settlement (7.6 days to cover).
No reported quarters with price history yet.
Percentile among 417 companies (100 = best)
Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | Compare |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
| GPCRStructure Therapeutics | $19.84 | −5.30% | −50.2% | — | — | — | $1.41B | Compare |
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | Compare |
| ZLABZai Lab Limited | $26.04 | −1.44% | +28.1% | −6.8% | −42.6% | — | $3.22B | Compare |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| QNRXQuoin Pharmaceuticals | $3.75 | −0.27% | −35.5% | — | — | — | $18.0M | Compare |
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
